AstraZeneca CEO doubles down on U.S. amid rumors of listing shift
-
最新报道：AstraZeneca CEO Pascal Soriot reaffirmed the company's commitment to the U.S. market amid speculation about a potential shift in its primary listing location. Soriot emphasized the importance of the U.S. for the pharmaceutical giant's growth, citing strong investor interest and market opportunities. The comments come as rumors swirl that AstraZeneca might consider moving its listing from London to New York, following similar moves by other UK-based firms. The company reported robust Q2 earnings, with revenue up 12% year-over-year, driven by strong sales of its cancer and rare disease treatments. Soriot also highlighted ongoing investments in R&D and pipeline expansion.
下一篇
3 Shocking Examples How BRICS Bypassed the US Dollar
- BRICS nations are increasingly bypassing the US dollar in trade settlements, with three no...
24小时热点
热点专题
410950